Biological and Ecological Department (DEB), University of Tuscia, 01100 Viterbo, Italy.
Department of Food and Drug, University of Parma, Viale delle Scienze, 27/A, 43124 Parma, Italy.
Front Biosci (Landmark Ed). 2018 Jan 1;23(6):997-1019. doi: 10.2741/4630.
Dengue is a mosquito-borne viral disease caused by four antigenically distinct serotypes of Dengue Virus (DENV), namely DENV1-4 and is currently considered the most important arthropod-born viral disease in the world. An effective antiviral therapy to treat Dengue Virus infection is still missing and a number of replicative cycle inhibitors are currently under study. Considering the rapid spreading of DENV and the common timeframe required for bringing a new drug on the market, the repurposing of approved drugs used for different diseases to identify novel inhibitors of this pathogen represents an attractive approach for a rapid therapeutic intervention. Herein, we will describe the most recent drug repurposing approaches to fight DENV infection and their implications in antiviral drug-discovery.
登革热是一种由四种具有不同抗原性的登革病毒(DENV)血清型引起的蚊媒病毒性疾病,分别为 DENV1-4,目前被认为是世界上最重要的节肢动物传播的病毒性疾病。目前仍缺乏有效的抗病毒疗法来治疗登革热病毒感染,许多复制周期抑制剂正在研究中。考虑到 DENV 的快速传播和将新药推向市场所需的常见时间框架,将用于治疗不同疾病的已批准药物重新用于寻找该病原体的新型抑制剂,是一种快速治疗干预的有吸引力的方法。在此,我们将描述最近用于对抗登革热病毒感染的药物再利用方法及其在抗病毒药物发现中的意义。